pioglitazone has been researched along with Glioma in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliomas are the most common primary tumors of the central nervous system." | 5.37 | Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion. ( Chen, J; Lan, Q; Ma, Y; Shao, B; Shen, A; Shi, J; Shi, W; Wan, Z, 2011) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "These data indicate that pioglitazone crosses the blood-brain barrier and has antineoplastic effects in this glioma xenograft model and may be of potential use in treatment of malignant gliomas." | 3.79 | The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. ( Blankenship, D; Caprariello, A; Dechant, A; Grommes, C; Karlo, JC; Landreth, GE, 2013) |
| "In this study the authors explored the benefits of treating C57B1/6 mice with an established intracerebral glioma by combining immunotherapy with interleukin (IL)-2-secreting syngeneic/allogeneic fibroblasts administered into the tumor bed along with the chemotherapeutic agent pioglitazone, a thiazolidinedione (TZD)." | 3.74 | Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. ( Cohen, EP; Feinstein, DL; Glick, RP; Lichtor, T; Lin, H; Spagnolo, A, 2007) |
| "Gliomas are the most common primary tumors of the central nervous system." | 1.37 | Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion. ( Chen, J; Lan, Q; Ma, Y; Shao, B; Shen, A; Shi, J; Shi, W; Wan, Z, 2011) |
| "Glioblastoma represent the most common primary brain tumor in adults and are currently considered incurable." | 1.35 | PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. ( Heneka, MT; Hermes, M; Kummer, MP; Orlandi, M; Papi, A; Tatenhorst, L; Terwel, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khoo, NK | 1 |
| Hebbar, S | 1 |
| Zhao, W | 1 |
| Moore, SA | 1 |
| Domann, FE | 1 |
| Robbins, ME | 1 |
| Ren, H | 1 |
| Gao, Z | 1 |
| Wu, N | 1 |
| Zeng, L | 1 |
| Tang, X | 1 |
| Chen, X | 1 |
| Liu, Z | 1 |
| Zhang, W | 1 |
| Wang, L | 1 |
| Li, Z | 1 |
| Tapia-Pérez, JH | 1 |
| Preininger, R | 1 |
| Kirches, E | 1 |
| Reinhold, A | 1 |
| Butzmann, J | 1 |
| Prilloff, S | 1 |
| Mawrin, C | 1 |
| Schneider, T | 1 |
| Papi, A | 1 |
| Tatenhorst, L | 1 |
| Terwel, D | 1 |
| Hermes, M | 1 |
| Kummer, MP | 1 |
| Orlandi, M | 1 |
| Heneka, MT | 2 |
| Grommes, C | 3 |
| Conway, DS | 1 |
| Alshekhlee, A | 1 |
| Barnholtz-Sloan, JS | 1 |
| Wan, Z | 1 |
| Shi, W | 1 |
| Shao, B | 1 |
| Shi, J | 1 |
| Shen, A | 1 |
| Ma, Y | 1 |
| Chen, J | 1 |
| Lan, Q | 1 |
| Karlo, JC | 1 |
| Caprariello, A | 1 |
| Blankenship, D | 1 |
| Dechant, A | 1 |
| Landreth, GE | 2 |
| Sastre, M | 1 |
| Beck, M | 1 |
| Feinstein, DL | 2 |
| Jacobs, AH | 1 |
| Schlegel, U | 1 |
| Spagnolo, A | 1 |
| Glick, RP | 1 |
| Lin, H | 1 |
| Cohen, EP | 1 |
| Lichtor, T | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
1 trial available for pioglitazone and Glioma
| Article | Year |
|---|---|
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
9 other studies available for pioglitazone and Glioma
| Article | Year |
|---|---|
Differential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy.
Topics: Animals; Astrocytes; Catalase; Chlorocebus aethiops; COS Cells; Gene Expression Regulation; Glioma; | 2013 |
Expression of REST4 in human gliomas in vivo and influence of pioglitazone on REST in vitro.
Topics: Alternative Splicing; Brain Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gli | 2015 |
Simultaneous Administration of Statins and Pioglitazone Limits Tumor Growth in a Rat Model of Malignant Glioma.
Topics: Animals; Brain Neoplasms; Disease Models, Animal; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2016 |
PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.
Topics: Analysis of Variance; Animals; Annexin A5; Antineoplastic Agents; bcl-2-Associated X Protein; Brain | 2009 |
Inverse association of PPARγ agonists use and high grade glioma development.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; P | 2010 |
Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Migration Assays; Cell Moveme | 2011 |
The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; | 2013 |
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Topics: Administration, Oral; Animals; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Bromodeoxyuri | 2006 |
Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Sur | 2007 |